Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

140 trials with published results (23%)

Research Maturity

409 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.2%

38 terminated out of 612 trials

Success Rate

91.5%

+5.0% vs benchmark

Late-Stage Pipeline

38%

233 trials in Phase 3/4

Results Transparency

34%

140 of 409 completed with results

Key Signals

140 with results91% success38 terminated

Data Visualizations

Phase Distribution

460Total
Not Applicable (82)
Early P 1 (1)
P 1 (55)
P 2 (89)
P 3 (130)
P 4 (103)

Trial Status

Completed409
Unknown101
Terminated38
Recruiting29
Active Not Recruiting11
Withdrawn11

Trial Success Rate

91.5%

Benchmark: 86.5%

Based on 409 completed trials

Clinical Trials (612)

Showing 20 of 20 trials
NCT07637214CompletedPrimary

A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal

NCT05551273Phase 2CompletedPrimary

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

NCT00001971Recruiting

Evaluation of Patients With Liver Disease

NCT07168356Phase 1Active Not RecruitingPrimary

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT03825458RecruitingPrimary

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

NCT00004850Completed

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT04914611RecruitingPrimary

Real World Assessment of People Living With Chronic Hepatitis B in Australia

NCT07589985RecruitingPrimary

Hep Mec Cohort in Zambia

NCT06497504Phase 2Active Not RecruitingPrimary

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT03933384Phase 4RecruitingPrimary

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

NCT05330455Phase 1TerminatedPrimary

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

NCT02366286CompletedPrimary

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

NCT03826433Phase 1RecruitingPrimary

hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

NCT05272735Phase 4TerminatedPrimary

HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

NCT05705427Phase 4CompletedPrimary

The COMBAT HBV Feasibility Trial

NCT06793826CompletedPrimary

Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

NCT05390424Not ApplicableRecruitingPrimary

Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot

NCT05856890Phase 1Recruiting

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

NCT01298037Active Not RecruitingPrimary

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

NCT01796457Active Not RecruitingPrimary

HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

Scroll to load more

Research Network

Activity Timeline